In addition, SNORD114‐17 is involved in several well‐known cancer‐related pathways, such as PI3K‐AKT signaling and the ECM receptor, suggesting that SNORD114‐17 may be an important regulator of the malignant phenotype. Here, SNORD114-17 is linked to cancer.